What are the side effect profiles of mycophenolate (mycophenolate mofetil) compared with azathioprine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mycophenolate vs Azathioprine Side Effect Profile

Mycophenolate mofetil is associated with significantly higher rates of gastrointestinal side effects (particularly diarrhea at 14% and GI bleeding requiring hospitalization in 3-5.4% of transplant patients), while azathioprine causes substantially more hepatotoxicity with elevated liver enzymes being the most common side effect (23% liver dysfunction). 1, 2, 3

Key Side Effect Differences

Gastrointestinal Toxicity

  • Mycophenolate causes more frequent and severe GI complications:

    • Diarrhea occurs in approximately 14% of patients 2
    • GI bleeding requiring hospitalization: 3% in renal, 1.7% in cardiac, and 5.4% in hepatic transplant patients 1
    • GI perforations occur rarely but are documented 1
    • These effects are dose-dependent and more pronounced with higher doses
  • Azathioprine has lower GI toxicity overall, though still present

Hepatotoxicity

  • Azathioprine demonstrates significantly higher liver toxicity:

    • Liver dysfunction occurs in 23% of patients 2
    • Significantly elevated AST, ALT, and GGT levels compared to mycophenolate (p = 0.03, p = 0.03, p = 0.01 respectively) 3
    • This is the most common reason for azathioprine discontinuation
  • Mycophenolate shows minimal hepatotoxicity

Overall Tolerability and Discontinuation Rates

Azathioprine is significantly more likely to be discontinued due to side effects than mycophenolate 2. In real-world data from 235 patients with myasthenia gravis, azathioprine had the highest discontinuation rate among immunosuppressants due to adverse effects 2.

Infection Risk

In cardiac transplant patients specifically, mycophenolate shows approximately 10% higher rates of opportunistic infections compared to azathioprine, particularly herpes virus infections (H. simplex, H. zoster, and cytomegalovirus) 1. However, this did not translate to excess mortality from infection/sepsis 1.

Hematologic Effects

Both agents can cause bone marrow suppression and should never be administered concomitantly 1. Complete blood counts should be monitored weekly during the first month, twice monthly for months 2-3, then monthly through the first year for mycophenolate 1.

Gender Considerations

Women experience higher frequencies of side effects from both agents, which is particularly relevant given teratogenicity concerns that already limit options in women of reproductive potential 2.

Clinical Implications

The choice between these agents should prioritize:

  1. Avoid azathioprine in patients with pre-existing liver disease or elevated transaminases
  2. Avoid mycophenolate in patients with active peptic ulcer disease, inflammatory bowel disease, or those unable to tolerate GI side effects 1
  3. Consider mycophenolate first-line when tolerability is the primary concern, as discontinuation rates are lower 2
  4. Monitor liver function tests closely with azathioprine (check at baseline, 2 weeks, then monthly for 3 months, then every 3 months)
  5. Counsel patients on mycophenolate about GI symptoms and the need for prompt reporting of severe diarrhea or bloody stools

Renal Impairment Caveat

In patients with severe chronic renal impairment (GFR < 25 mL/min/1.73 m²), mycophenolate doses should not exceed 1g twice daily, and patients require careful monitoring due to accumulation of metabolites 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.